Loading clinical trials...
Loading clinical trials...
An Open-Label Study to Determine the Safety and Pharmacokinetics of AT1001 in Subjects With Impaired Renal Function and Healthy Subjects With Normal Renal Function (AT1001-015)
Conditions
Interventions
AT1001 150 mg
Locations
4
United States
GSK Investigational Site
Costa Mesa, California, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Orlando, Florida, United States
Start Date
August 1, 2011
Primary Completion Date
April 1, 2012
Completion Date
April 1, 2012
Last Updated
August 3, 2017
NCT07382128
NCT05923788
NCT07277361
NCT04252066
NCT06226987
NCT06065852
Lead Sponsor
Amicus Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions